только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 11 / 21
Страница 5 / 27

Список литературы

129. Trenkwalder C, Kies B, Rudzinska M, et al. The RECOVER Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double- blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26: 90–99

130. Hely MA, Morris JG, Reid WG, et al. The Sydney Multicentre Study of Parkinson’s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994; 57: 903– 910.

131. Jorgensen PB, Bergin JD, Haas L, et al. Controlled trial of amantadine hydrochloride in Parkinson’s disease. N Z Med J 1971; 73: 263–267.

132. Goetz CG, Shannon KM, Tanner CM, Carroll VS, Klawans HL. Agonist substitution in advanced Parkinson’s disease. Neurology 1989; 39: 1121–1122.

133. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson’s disease: is rapid titration preferable to slow? Neurology 1999; 52: 1227–1229.

134. Canesi M, Antonini A, Mariani CB, et al. An overnight switch to ropinirole therapy in patients with Parkinson’s disease. Short communication. J Neural Transm 1999; 106: 925–929.

135. Gimenez-Roldan S, Esteban EM, Mateo D. Switching from bromocriptine to ropinirole in patients with advanced Parkinson’s disease: open label pilot responses to three different dose-ratios. Clin Neuropharmacol 2001; 24: 346–351.

136. Chen X, Ren C, Li J, Wang S, Dron L, Harari O, Whittington C. The Efficacy and Safety of Piribedil Relative to Pramipexole for the Treatment of Early Parkinson Disease: A Systematic Literature Review and Network Meta-Analysis. Clin Neuropharmacol. 2020 Jul/Aug;43(4):100-106

137. Reichmann H, Herting B, Miller A, Sommer U. Switching and combining dopamine agonists. J Neural Transm 2003; 110: 1393–1400.

138. Grosset K, Needleman F, Macphee G, Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson’s disease: a clinical series and five-drug dose conversion table. Mov Disord 2004; 19: 1370–1374.

139. Lewitt PA, Boroojerdi B, Macmahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol 2007; 30: 256–265.

140. Linazasoro G. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson’s disease. Spanish Dopamine Agonists Study Group. J Neurol 2004; 251: 335–339.

141. Rascol O, Barone P, Hauser RA, et al. Efficacy, safety, and tolerability of overnight switching from immediatet o once daily extended-release pramipexole in early Parkinson’s disease. The Pramipexole Switch Study Group. Mov Disord 2010; 25: 2326–2332.

142. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled- release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999; 53: 1012–1019.

143. Goetz CG, Tanner CM, Shannon KM, et al. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson’s disease patients with and without motor fluctuations. Neurology 1988; 38: 1143–1146.

144. Lees AJ. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson’s disease. Eur Neurol 1987; 27(Suppl. 1): 126–134.

145. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997; 37: 23–27.

146. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010; 68: 18–27.

147. Parkes JD, Baxter RC, Marsden CD, Rees JE. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1974; 37: 422–426.

148. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson’s disease: an evidence-based review. Mov Disord 2002; 17(Suppl. 4): S1–S166.

149. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev 2003; 2:CD003735.

150. Lees A.J. The on-off phenomenon. Journal of Neurology, Neurosurgery, Psychiatry 1989; 52: 29-37.

151. Brooks DJ, Sagar H. UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003; 74: 1071–1079.

152. Fung VS, Herawati L, Wan Y. Movement Disorder Society of Australia Clinical Research and Trials Group, QUEST-AP Study Group. Quality of life in early Parkinson’s disease treated with levodopa/carbidopa/entacapone. Mov Disord 2009; 24: 25–31.

153. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s disease. The FIRST-STEP Study Group. Mov Disord 2009; 24: 541–550

154. Yi ZM, Qiu TT, Zhang Y, Liu N, Zhai SD. Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation. Ther Clin Risk Manag. 2018 Apr 16;14:709-719. doi: 10.2147/TCRM.S163190. PMID: 29713179; PMCID: PMC5907888.

155. Brooks DJ, Sagar H; UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071- 9. doi: 10.1136/jnnp.74.8.1071. PMID: 12876237; PMCID: PMC1738605.